Autoantibodies and gastrointestinal symptoms in infertile women in relation to in vitro fertilization

BMC Pregnancy and Childbirth

Bodil Ohlsson¹  Thomas Mandl²  Mariette Bengtsson³  Bodil Roth¹  Oskar Hammar¹ 

[1] Department of Clinical Sciences, Division of Internal Medicine, Skåne University Hospital, Lund University, 205 02, Malmö, Sweden;Department of Clinical Sciences, Division of Rheumatology, Skåne University Hospital, Lund University, 205 02, Malmö, Sweden;Faculty of Health and Society, Institution of Care Science, Malmö University, Malmö, Sweden

关键词: Luteinizing hormone;    In vitro fertilization;    Gonadotropin-releasing hormone;    Gastrointestinal symptoms;    Abdominal pain;   

Others  :  1132297
DOI  :  10.1186/1471-2393-13-201

 received in 2013-06-14, accepted in 2013-10-31,  发布年份 2013

【 摘 要 】

Background

Prior reports suggest a link between gonadotropin-releasing hormone (GnRH) and gastrointestinal function. The aim of the study was to prospectively investigate women subjected to in vitro fertilization (IVF) using the GnRH analog buserelin, taking into account gastrointestinal symptoms and antibody development against buserelin, GnRH, luteinizing hormone (LH), and their receptors.

Methods

Gastrointestinal symptoms were registered by the Visual Analogue Scale for Irritable Bowel Syndrome (VAS-IBS) before and after IVF treatment, and five years later. Health-related quality of life was evaluated by the 36-item Short-Form questionnaire (SF-36). ELISA was used for antibody analyses before and after treatment. Data were compared with women from the general population.

Results

In total, 124 patients were investigated before and after IVF, and 62 were re-evaluated after five years. Buserelin treatment led to significant impairment of constipation (p = 0.004), nausea and vomiting (p = 0.035), psychological well-being (p = 0.000), and the intestinal symptoms’ influence on daily life (p = 0.027). At 5-year follow-up, abdominal pain was worsened (p = 0.041), but psychological well-being was improved (p = 0.036), compared to prior treatment, and 15% had an observable deterioration in gastrointestinal symptoms. None developed severe dysmotility. Patients had higher prevalence of IgG antibodies against LH (p = 0.001) and its receptor (p = 0.016), and IgM antibodies against the GnRH receptor (p = 0.001) prior treatment compared with controls, but no antibody development was observed after IVF.

Conclusion

Patients experience gastrointestinal symptoms during buserelin treatment, and abdominal pain is still increased after five years, but buserelin does not increase antibody formation against GnRH, LH or their receptors.

【 授权许可】

   
2013 Hammar et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Quigley EM, Bytzer P, Jones R, Mearin F: Irritable bowel syndrome: the burden and unmet needs in Europe. Dig Liver Dis 2006, 38:717-723.
• [2]Wald A, Van Thiel DH, Hoechstetter L, Gavaler JS, Egler KM, Verm R, Scott L, Lester R: Gastrointestinal transit: the effect of the menstrual cycle. Gastroenterology 1981, 80:1497-1500.
• [3]Gonenne J, Esfandyari T, Camilleri M, Burton DD, Stephens DA, Baxter KL, Zinsmeister AR, Bharucha AE: Effect of female sex hormone supplementation and withdrawal on gastrointestinal and colonic transit in postmenopausal women. Neurogastroenterol Motil 2006, 18:911-918.
• [4]Conn PM, Crowley WF Jr: Gonadotropin-releasing hormone and its analogs. Annu Rev Med 1994, 45:391-405.
• [5]Huang W, Yao B, Sun L, Pu R, Wang L, Zhang R: Immunohistochemical and in situ hybridization studies of gonadotropin releasing hormone (GnRH) and its receptor in rat digestive tract. Life Sci 2001, 68:1727-1734.
• [6]Khanna R, Browne RM, Heiner AD, Clench MH, Mathias JR: Leuprolide acetate affects intestinal motility in female rats before and after ovariectomy. Am J Physiol 1992, 262:G185-190.
• [7]Hammar O, Ohlsson B, Veress B, Alm R, Fredrikson GN, Montgomery A: Depletion of enteric gonadotropin-releasing hormone is found in a few patients suffering from severe gastrointestinal dysmotility. Scand J Gastroenterol 2012, 47:1165-1173.
• [8]Ohlsson B, Sjoberg K, Alm R, Fredrikson GN: Patients with irritable bowel syndrome and dysmotility express antibodies against gonadotropin-releasing hormone in serum. Neurogastroenterol Motil 2011, 23:1000-1006.
• [9]Mathias JR, Clench MH, Abell TL, Koch KL, Lehman G, Robinson M, Rothstein R, Snape WJ: Effect of leuprolide acetate in treatment of abdominal pain and nausea in premenopausal women with functional bowel disease: a double-blind, placebo-controlled, randomized study. Dig Dis Sci 1998, 43:1347-1355.
• [10]Palomba S, Orio F Jr, Manguso F, Russo T, Falbo A, Lombardi G, Doldo P, Zullo F: Leuprolide acetate treatment with and without coadministration of tibolone in premenopausal women with menstrual cycle-related irritable bowel syndrome. Fertil Steril 2005, 83:1012-1020.
• [11]Ohlsson B, Veress B, Janciauskiene S, Montgomery A, Haglund M, Wallmark A: Chronic intestinal pseudo-obstruction due to buserelin-induced formation of anti-GnRH antibodies. Gastroenterology 2007, 132:45-51.
• [12]Sand E, Voss U, Hammar O, Alm R, Nordin Fredrikson G, Ohlsson B, Ekblad E: Gonadotropin-releasing hormone analog buserelin causes neuronal loss in rat gastrointestinal tract. Cell Tissue Res 2013, 351:521-534.
• [13]Bengtsson M, Ohlsson B, Ulander K: Development and psychometric testing of the Visual Analogue Scale for Irritable Bowel Syndrome (VAS-IBS). BMC Gastroenterol 2007, 7:16. BioMed Central Full Text
• [14]Bengtsson M, Persson J, Sjölund K, Ohlsson B: Further psychometric testing of the Visual Analogue Scale for Irritable Bowel Syndrome (VAS-IBS) after use in clinical practice. Gastroenterol Nurs 2013, 36:188-198.
• [15]Ware JE: SF-36 health survey: Manual and interpretation guide. Boston MA: New England Medical Center, The Health Institute; 1993.
• [16]Scoggins JF, Patrick DL: The use of patient-reported outcomes instruments in registered clinical trials: evidence from ClinicalTrials.gov. Contemp Clin Trials 2009, 30:289-292.
• [17]Ware JE Jr: SF-36 health survey update. Spine (Phila Pa 1976) 2000, 25:3130-3139.
• [18]Roth B, Ohlsson B: Gastrointestinal symptoms and psychological well-being in patients with microscopic colitis. Scand J Gastroenterol 2013, 48:27-34.
• [19]Trabant H, Widdra W, de Looze S: Efficacy and safety of intranasal buserelin acetate in the treatment of endometriosis: a review of six clinical trials and comparison with danazol. Prog Clin Biol Res 1990, 323:357-382.
• [20]Eugster A, Vingerhoets AJ: Psychological aspects of in vitro fertilization: a review. Soc Sci Med 1999, 48:575-589.
• [21]Mathias JR, Clench MH: Relationship of reproductive hormones and neuromuscular disease of the gastrointestinal tract. Dig Dis 1998, 16:3-13.
• [22]Soldani G, Del Tacca M, Bambini G, Polloni A, Bernardini C, Martinotti E, Martino E: Effects of gonadotropin-releasing hormone (GnRH) on gastric secretion and gastrin release in the dog. J Endocrinol Invest 1982, 5:393-6.
• [23]Chen L, Sun XD, Zhao J, Yang AG, Huang WQ: Distribution, cloning and sequencing of GnRH, its receptor, and effects of gastric acid secretion of GnRH analogue in gastric parietal cells of rats. Life Sci 2005, 76:1351-1365.
• [24]Gama P, Alvares EP: LHRH and somatostatin effects on the cell proliferation of the gastric epithelium of suckling and weaning rats. Regul Pept 1996, 63:73-78.
• [25]Ohlsson B, Ekblad E, Veress B, Montgomery A, Janciauskiene S: Antibodies against gonadotropin-releasing hormone (GnRH) and destruction of enteric neurons in 3 patients suffering from gastrointestinal dysfunction. BMC Gastroenterol 2010, 10:48. BioMed Central Full Text
• [26]Chen L, He HX, Sun XD, Zhao J, Liu LH, Huang WQ, Zhang RQ: Expression of gonadotropin-releasing hormone receptor and effect of gonadotropin-releasing hormone analogue on proliferation of cultured gastric smooth muscle cells of rats. World J Gastroenterol 2004, 10:1780-1784.
• [27]White CD, Stewart AJ, Lu ZL, Millar RP, Morgan K: Antiproliferative effects of GnRH agonists: prospects and problems for cancer therapy. Neuroendocrinology 2008, 88:67-79.
• [28]Aguilar-Rojas A, Huerta-Reyes M: Human gonadotropin-releasing hormone receptor-activated cellular functions and signaling pathways in extra-pituitary tissues and cancer cells (Review). Oncol Rep 2009, 22:981-990.
• [29]Naor Z: Signaling by G-protein-coupled receptor (GPCR): studies on the GnRH receptor. Front Neuroendocrinol 2009, 30:10-29.
• [30]Wang L, Wu J, Cao H, Chen R, Zhang N, Fu J, Gao B, Zhang J, Hou R, Tang C, Ji Q: The correlation between intestinal gonadotropin-releasing hormone (GnRH) and proglucagon in hyperlipidemic rats and Goto-Kakizaki (GK) rats. Endocr Pathol 2009, 20:227-234.
• [31]Ducker TE, Boss JW, Altug SA, Mehrabian H, Dekeratry DR, Clench MH, Mathias JR: Luteinizing hormone and human chorionic gonadotropin fragment the migrating myoelectric complex in rat small intestine. Neurogastroenterol Motil 1996, 8:95-100.
• [32]Hammar O, Veress B, Montgomery A, Ohlsson B: Expression of Luteinizing Hormone Receptor in the Gastrointestinal Tract in Patients with and without Dysmotility. Drug Target Insights 2012, 6:13-18.
• [33]Wang F, Zhen TZ, Li W, Qu SY, He DY: Action of progesterone on contractile activity of isolated gastric strips in rats. World J Gastroenterol 2003, 9:775-778.
• [34]Kamel RM: Management of the infertile couple: an evidence-based protocol. Reprod Biol Endocrinol 2010, 8:21. BioMed Central Full Text
• [35]Luborsky JL, Yu Y, Edassery SL, Jaffar J, Yip YY, Liu P, Hellstrom KE, Hellstrom I: Autoantibodies to mesothelin in infertility. Cancer Epidemiol Biomarkers Prev 2011, 20:1970-1978.
• [36]Meyer WR, Lavy G, DeCherney AH, Visintin I, Economy K, Luborsky JL: Evidence of gonadal and gonadotropin antibodies in women with a suboptimal ovarian response to exogenous gonadotropin. Obstet Gynecol 1990, 75:795-799.
• [37]Pires ES, Khole VV: A block in the road to fertility: autoantibodies to heat-shock protein 90-beta in human ovarian autoimmunity. Fertil Steril 2009, 92:1395-1409.
• [38]Tanriverdi F, Silveira LFG, MacColl GS, Bouloux PMG: The hypothalamic-pituitary-gonadal axis: immune function and autoimmunity. J Endocrinol 2003, 176:293-304.
• [39]Sand E, Bergvall M, Ekblad E, D´Atamo M, Ohlsson B: Expression and distribution of GnRH, LH, FSH and their receptors in gastrointestinal tract from man and rat. Reg Peptides 2013. 10.1016/j.regpep.2013.09.002. [Epub ahead of print]
• [40]Agreus L, Svardsudd K, Nyren O, Tibblin G: Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 1995, 109:671-680.
• [41]Finnstrom O, Kallen B, Lindam A, Nilsson E, Nygren KG, Olausson PO: Maternal and child outcome after in vitro fertilization–a review of 25 years of population-based data from Sweden. Acta Obstet Gynecol Scand 2011, 90:494-500.